Alnylam Pharmaceuticals
Price & Volume
Stats
See more52W Range | $205.87-$495.55 |
Market Cap | $57.6B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $3.2B |
Revenue Growth (YoY) | 149.3% |
Gross Profit (12 Mos) | $2.6B |
Diluted EPS | $0.31 |
News
See moreYahoo Finance • 20 hours ago
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3
Yahoo Finance • 8 days ago
Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth
Yahoo Finance • 8 days ago
Hemophilia B Research Report 2025-2035: Market Led by UniQure, Pfizer, Novo Nordisk, HEMA Biologics, and Alnylam Pharmaceuticals as Next-Generation Therapies and R&D Investment Drive Innovation
Yahoo Finance • 13 days ago
Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook
About
CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
CFO | Mr. Jeffrey V. Poulton M.B.A. |
Address | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 2,230 |
